Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation)

The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials have demonstrated the clinical benefit as well as the long-term effect of these drugs. Currently, the problem of treatment of patients after disease progression against the background of the use of checkpoint inhibitors is relevant. Equally relevant is the issue of choosing the correct and most effective treatment tactics for NSCLC patients with oligoprogression, as well as with abscopal effect. This paper describes a clinical case of a patient with lung adenocarcinoma without driver mutations with PD-L1-positive status, who was treated with nivolumab after second-line chemotherapy for disease progression, and after oligoprogression of the disease into the brain was given stereotactic radiotherapy of metastatic lesion and continued therapy with nivolumab. Partial regression of metastases was achieved with a prolonged effect on the background of continued treatment with nivolumab for 24 months. Tolerability of therapy was satisfactory: no adverse events were observed. The patient retained the result for 1.5 years.

1. Miller K.D., Goding Sauer A., Ortiz A.P., Fedewa S.A., Pinheiro P.S., Tortolero-Luna G. et al. Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018;68:425-445. https://doi.org/10.3322/caac.21494.

2. Vladimirova L.Yu., Storozhakova A.E., Popova I.L., Kabanov S.N., Abramova N.A., Teplyakova M.A. et al. Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases). Meditsinskiy Sovet. 2021;(9):64-74. (In Russ.) https://doi.org/10.21518/2079-701X-2021-9-64-74.

3. Reck M., Rodriguez-Abreu D., Robinson A.G., Hui R., Csoszi T., Brahmer J.R. et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. https://doi.org/10.1200/JCO.18.00149.

4. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627-1639. https://doi.org/10.1056/NEJMoa1507643.

5. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell NonSmall-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-135. https://doi.org/10.1056/NEJMoa1504627.

6. Herbst R.S., Baas P., Kim D.W., Felip E., Perez-Gracia J.L., Han J.Y. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A Randomised Controlled Trial. Lancet. 2016;387(10027):1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7.

7. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. https://doi.org/10.1016/S0140-6736(16)32517-X.

8. Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R. et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929. https://doi.org/10.1056/NEJMoa1709937.

9. Reck M., Rodriguez-Abreu D., Robinson A.G., Hui R., Csoszi T., Brahmer J.R. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-smallcell lung cancer. N Engl J Med. 2016;375(19):1823-1833. https://doi.org/10.1056/NEJMoa1606774.

10. Gandhi L., Rodriguez-Abreu D., Gadgeel S., Esteban E., Felip E., Garassino M.C. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. https://doi.org/10.1056/NEJMoa1801005.

11. Pollack M.H., Betof A., Dearden H., Rapazzo K., Valentine I., Shoushtari A.N. et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250-255. https://doi.org/10.1093/annonc/mdx642.

12. Lebbe C., Weber J.S., Maio M., Neyns B., Harmankaya K., Wolchok J.D. et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014;25(11):2277-2284. https://doi.org/10.1093/annonc/mdu441.

13. Watanabe H., Kubo T., Ninomiya K., Kudo K., Minami D., Murakami E. et al. The effect and safety of immune checkpoint inhibitor rechallenge in non small cell lung cancer. Jpn J Clin Oncol. 2019;49(8):762-765. https://doi.org/10.1093/jjco/hyz066.

14. Fujita K., Uchida N., Kanai O., Okamura M., Nakatani K., Mio T. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: Emerging reports of 12 cases. Cancer Chemother Pharmacol. 2018;81(6):1105-1109. https://doi.org/10.1007/s00280-018-3585-9.

15. Nayak L, Lee E.Q., Wen P.Y. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48-54. https://doi.org/10.1007/s11912-011-0203-y.

16. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T. et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751. https://doi.org/10.1016/s0360-3016(96)00619-0.

17. Sperduto P.W., Kased N., Roberge D., Xu Z., Shanley R., Luo X. et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419-425. https://doi.org/10.1200/JCO.2011.38.0527.

18. Lee D.H., Han J.Y., Kim H.T., Yoon S.J., Pyo H.R., Cho K.H. et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer. 2008;113(1):143-149. https://doi.org/10.1002/cncr.23526.

19. Attia А., Page B.P., Lesser G.J., Chan M. Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol. 2014;15(4):539-550. https://doi.org/10.1007/s11864-014-0307-3.

20. Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E. Metastatic nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl. 7):vii56-vii64. https://doi.org/10.1093/annonc/mds226.

21. Robinet G., Thomas P., Breton J.L., Lena H., Gouva S., Dabouis G. et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Frangais de Pneumo-Cancerologie (GFPC) protocol 95-1. Ann Oncol. 2011;12(1):59-67. https://doi.org/10.1023/a:1008338312647.

22. Besse В., Le Moulec S., Senellart H., Mazieres J., Barlesi F., Dansin E. et al. Phase II study of bevacizumab in combination with first-line chemotherapy or second-line erlotinib in non-squamous NSCLC patients with asymptomatic untreated brain metastases (ML21823). Ann Oncol. 2012;23:ix426. https://doi.org/10.1016/S0923-7534(20)33897-7.

23. Goldberg S.B., Gettinger S.N., Mahajan A., Chiang A.C., Herbst R.S., Sznol M. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-ran-domised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976-983. https://doi.org/10.1016/S1470-2045(16)30053-5.

24. Chargari C., Magne N., Guy J.-B., Rancoule C., Levy A., Goodman K.A., Deutsch E. Optimize and refine therapeutic index in radiation therapy: overview of a century. Cancer Treat Rev. 2016;45:58-67. https://doi.org/10.1016/j.ctrv.2016.03.001.

25. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256-265. https://doi.org/10.1093/jnci/djs629.

26. Frey B., Ruckert M., Deloch L., Ruhle P.F., Derer A., Fietkau R., Gaipl U.S. Immunomodulation by ionizing radiation-impact for design of radioimmunotherapies and for treatment of inflammatory diseases. Immunol Rev. 2017;280(1):231-248. https://doi.org/10.1111/imr.12572.